Nebulizer Versus Handheld Maintenance Therapy for Patients With COPD
RecruitingPhase 4
Who can join
Ages 60 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * \> 10 pack-years smoking cigarettes * Diagnosis of COPD based on GOLD Criteria * Patients are clinically stable for the past 4 weeks * Prior Pulmonary function tests showing FEV1 \< 50% predicted (either 30 minutes post albuterol or within 2-4 hours after using their maintenance long-acting inhaler) within the past 12 months. * Currently using a single pMDI or a single DPI with either LABA/LAMA or LABA/LAMA/ICS therapy for at least one month. Exclusion Criteria: * Current diagnosis of dementia or known cognitive impairment. * Current impairment in manual dexterity (i.e., severe rheumatoid arthritis, severe tremor, etc) * Exacerbation of COPD within the last 2 months * Current diagnosis of other respiratory disease including asthma, treatment with a LABA/LAMA slow mist inhaler or treatment with SABA/SAMA nebulizer medications 3-4 times per day as maintenance therapy * Current use of daily Prednisone as treatment for COPD
About the study
Multi-site, randomized controlled trial to determine whether patients who report NO symptomatic benefit with their maintenance hand-held inhaler(s), benefit upon switching to nebulized therapy using comparable classes of medications.
What is being tested
- Nebulized therapy of similar medication solutions (device)
- Continue handheld therapy (device)
Sponsor: COPD Foundation · Participants: 120 · Started: Jul 14, 2026
Contact the study team
Official record on ClinicalTrials.gov — NCT07816835
Locations in the U.S.
| Missouri | Midwest Chest Consultants, P.C., Saint Charles |
| North Carolina | Southeastern Research Center, Winston-Salem |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.